Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection by Bullement, A. et al.
This is a repository copy of Evaluation of survival extrapolation in immuno-oncology using 
multiple pre-planned data cuts: learnings to aid in model selection.




Bullement, A. orcid.org/0000-0001-7091-0972, Willis, A., Amin, A. et al. (3 more authors) 
(2020) Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned 
data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 20. 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH ARTICLE Open Access
Evaluation of survival extrapolation in
immuno-oncology using multiple
pre-planned data cuts: learnings to aid in
model selection
Ash Bullement1, Anna Willis2, Amerah Amin3, Michael Schlichting4, Anthony James Hatswell1,5 and Murtuza Bharmal6*
Abstract
Background: Due to limited duration of follow up in clinical trials of cancer treatments, estimates of lifetime
survival benefits are typically derived using statistical extrapolation methods. To justify the method used, a range of
approaches have been proposed including statistical goodness-of-fit tests and comparing estimates against a
previous data cut (i.e. interim data collected). In this study, we extend these approaches by presenting a range of
extrapolations fitted to four pre-planned data cuts from the JAVELIN Merkel 200 (JM200) trial. By comparing
different estimates of survival and goodness-of-fit as JM200 data mature, we undertook an iterative process of
fitting and re-fitting survival models to retrospectively identify early indications of likely long-term survival.
Methods: Standard and spline-based parametric models were fitted to overall survival data from each JM200 data
cut. Goodness-of-fit was determined using an assessment of the estimated hazard function, information theory-
based methods and objective comparisons of estimation accuracy. Best-fitting extrapolations were compared to
establish which one provided the most accurate estimation, and how statistical goodness-of-fit differed.
Results: Spline-based models provided the closest fit to the final JM200 data cut, though all extrapolation methods
based on the earliest data cut underestimated the ‘true’ long-term survival (difference in restricted mean survival
time [RMST] at 36 months: − 1.1 to − 0.5 months). Goodness-of-fit scores illustrated that an increasingly flexible
model was favored as data matured. Given an early data cut, a more flexible model better aligned with clinical
expectations could be reasonably justified using a range of metrics, including RMST and goodness-of-fit scores
(which were typically within a 2-point range of the statistically ‘best-fitting’ model).
Conclusions: Survival estimates from the spline-based models are more aligned with clinical expectation and provided a
better fit to the JM200 data, despite not exhibiting the definitively ‘best’ statistical goodness-of-fit. Longer-term data are
required to further validate extrapolations, though this study illustrates the importance of clinical plausibility when selecting
the most appropriate model. In addition, hazard-based plots and goodness-of-fit tests from multiple data cuts present useful
approaches to identify when a more flexible model may be advantageous.
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Background
Immuno-oncology treatments aim to exploit the body’s
immune system to target and kill cancer cells [1]. Different
‘immunotherapy’ classes have been studied in a range of
cancers, though perhaps one of the most notable advances
in contemporary medicine has been the development of
immune-checkpoint inhibitors [1–3]. Immune-checkpoint
inhibitors were first licensed for use in melanoma,
followed by a number of other cancers including non-
small-cell lung cancer, renal cell carcinoma and urothelial
carcinoma [4]. More recent approvals have included the
use of immune-checkpoint inhibitors in rare cancers, such
as microsatellite instability-high or mismatch repair defi-
cient solid tumors [4].
Clinical trials facilitate the collection of data regarding
the safety and efficacy of the intervention(s) under study
however data collection is subject to a number of limita-
tions. These include the number and characteristics of
patients recruited, the generalizability of the study design
to clinical practice, and the duration over which data are
collected. The latter of these limitations (known as ad-
ministrative censoring) plays a key role when establish-
ing the clinical- and cost-effectiveness of interventions.
There is a growing trend in accelerated or conditional
approvals and breakthrough designations being granted
by the Food and Drugs Administration (FDA) and the
European Medicines Agency (EMA) meaning it is more
often the case that interim analyses are used to inform
regulatory submissions, which are subsequently updated
as further data are collected [5, 6].
Long-term outcomes are typically uncertain at the
time of both regulatory and reimbursement assessment.
Survival extrapolation is often used to estimate longer-
term outcomes in support of reimbursement applica-
tions, which typically consider outcomes over a patient’s
lifetime, however parametric estimates of survival (per-
mitting inspection of both short- and long-term survival)
have also factored into regulatory decisions [7, 8]. Estab-
lishing a robust estimate of OS for patients treated with
immune-checkpoint inhibitors is of increased import-
ance versus conventional systemic anticancer therapies,
as a substantial proportion of the treatment benefit is
anticipated to manifest in the longer term (i.e. beyond
the duration follow-up typically available at the time of
regulatory or reimbursement assessment).
Guidance for undertaking survival analysis of patient-
level data is available from a number of sources; includ-
ing the commonly-cited National Institute for Health
and Care Excellence (NICE) Decision Support Unit
(DSU) Technical Support Document (TSD) 14 [9–16].
TSD14 offers practical, transparent guidance for under-
taking survival analysis regardless of therapeutic area
and/or the mechanistic properties of interventions being
assessed. Within TSD14, it is noted that the most popu-
lar types of survival extrapolation models submitted for
review by NICE are parametric survival models (PSMs),
which are commonly used internationally [9, 16–18].
PSMs assume the underlying survivor function may be
represented by a statistical distribution; ranging in both
complexity and flexibility, which may be compared using
standard statistical tests. PSMs do not require any spe-
cific assumptions to be fitted, though the appropriate-
ness of a specific PSM for a given data set may be
determined through an interrogation of the patient-level
data; hence PSMs are a popular choice of extrapolation
method to inform submissions of evidence to regulatory
and reimbursement agencies.
In this study, we present a range of PSMs to predict
OS beyond the observed period in a case study clinical
trial (JAVELIN Merkel 200 [JM200] of avelumab [Baven-
cio®] for patients with metastatic Merkel cell carcinoma
[mMCC], NCT02155647) [19]. PSMs were fitted to four
pre-planned published trial data cuts in order to estab-
lish how predictions changed over time, and assess the
accuracy of initial projections versus data later made
available. By re-fitting and testing the accuracy of model
predictions, it is possible to retrospectively identify
emergent evidence of likely long-term survival outcomes
and, by extension, inform best modelling practice.
Methods
Motivating example
The motivating example used in this study was the
single-arm (i.e. uncontrolled), Phase II JM200 trial of
avelumab for the treatment of mMCC. Including the
data submitted to the FDA, a total of four distinct pre-
planned data cuts from Part A of the JM200 trial (con-
ducted in treatment-experienced mMCC) have been
published, providing information regarding the evolving
pattern of OS as data from the trial mature. Within the
context of this study, each data cut refers to the mini-
mum follow-up data available for all patients that are
still being followed up for OS within the study – e.g. a
“12-month” data cut refers to the interim data collected
up until all patients had been followed up until at least
12 months (though some patients may have been
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followed up for longer). The term “pre-planned interim
analysis” has also been used to describe different data
cuts in other studies.
Data from JM200 offer a unique opportunity to retro-
spectively assess the accuracy of survival projections over
a number of data cuts, particularly when acknowledging
that at the time data from JM200 were published, sur-
vival outcomes for patients with mMCC receiving stand-
ard care were poor (median OS of approximately 5.3
months for patients with distant mMCC following
second-line chemotherapy in Europe) [20–22]. Conse-
quently, little was known around the likely long-term
outcomes associated with avelumab treatment in an
mMCC population. The key features of these data cuts
are summarized in Table 1.
Assessment of data
Patient-level data from each data cut were assessed fol-
lowing guidance from TSD14, from which suitable PSMs
were identified for fitting. TSD14 recommends the use
of hazard-based plots to inform appropriate model selec-
tion. As data from the (single-arm) JM200 trial are only
available for patients receiving avelumab, some aspects
of TSD14 are irrelevant (e.g. testing for proportional
hazards between multiple treatment groups).
All analyses were performed using the statistical soft-
ware R [27]. The package ‘muhaz’ was used to produce
smoothed hazard estimates to aid selection of appropri-
ate PSMs. Smoothed hazard plots provide an illustration
of how the estimated hazard of death changes over time,
allowing for inference to be made around which PSMs
would be expected to provide a good fit to the data, and
thus yield plausible survival estimates. PSMs were
rejected where the smoothed hazard plots demonstrated
a clear violation of the model functional form – for ex-
ample, were the smoothed hazard plot to demonstrate a
monotonically-increasing pattern of hazards over time,
the exponential model (which assumes a constant hazard
rate) would be rejected.
Empirical hazard plots (e.g. number of events per
month) have been considered in a previous study as an
alternative representation of the estimated hazard func-
tion (where time is considered on a continuous scale),
however these plots would have limited use to inform
appropriate model selection within the context of the
JM200 trial due to its small sample size (n = 88) [28].
This is because there will be several periods over which
the hazard of death would be estimated as zero as no
events may have occurred within a given timeframe.
Smoothed hazard plots are not affected by this issue to
the same extent, hence were preferred for this study.
Fitted models
The focus of this study was on the use of PSMs that do
not require implicit or explicit assumptions regarding
the patient population, disease area, or therapeutic class
of the intervention. As such, two different types of PSMs
were fitted: [1] standard PSMs, and [2] Royston and Par-
mar spline-based PSMs [29]. The R package ‘flexsurv’
was used to fit both standard and spline-based PSMs
[30]. Other modelling approaches (such as cure-based or
mixture models) were not considered as these require
the estimation and/or specification of mixing weights or
cure probabilities. No specific parametric modelling ap-
proaches were pre-specified in the JM200 study proto-
col, and so while each of the modelling approaches may
be considered post-hoc analyses, this is not unusual with
the context of survival extrapolation.
The standard PSMs considered were the exponential,
Weibull, Gompertz, lognormal, log-logistic, and general-
ized gamma, in line with guidance from TSD14. These
PSMs are commonly used as the range of candidate
PSMs in economic evaluations of cancer interventions.
As discussed previously, the exponential PSM assumes a
constant hazard rate over time, whereas both the
Weibull and Gompertz PSMs assume a monotonically
increasing or decreasing hazard rate over time (exclud-
ing the special case of the Weibull wherein the shape
parameter = 1, in which case it is equivalent to the expo-
nential PSM). The lognormal, log-logistic, and general-
ized gamma models do not assume a monotonic hazard
rate over time, and as such are able to reflect turning
points in the underlying hazard function. TSD14 pro-
vides a more detailed summary of each of the standard
PSMs.
Spline-based PSMs use natural, cubic, piecewise poly-
nomials to smooth between sections of a transformation
of the baseline survivor function.1 The number of sec-
tions is based on a specified number of ‘knots’ (equiva-
lent to cut-points), and the fit within each section is
based on a selected functional form. A detailed explan-
ation of spline-based PSMs is provided by Royston and
Table 1 Data cuts from Part A of the JAVELIN Merkel 200 clinical trial
Label Database lock Minimum patient follow-up Source(s)
12mo September 3, 2016 12 months Kaufman et al., (2018) [23]
18mo March 24, 2017 18 months D’Angelo et al., (2018) [24]
24mo September 26, 2017 24 months Nghiem et al., (2018) [25]
36mo September 14, 2018 36 months D’Angelo et al., (2020) [26]
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Parmar (2002) [29]; though to summarize, Royston and
Parmar suggest the use of these flexible parameteriza-
tions to better reflect the “behavior” of the hazard rate
over time.
In our study, we fitted spline-based PSMs assuming
functional forms that are extensions of the Weibull, log-
logistic and log-normal standard PSMs – henceforth re-
ferred to as hazard, odds, or normal spline-based PSMs,
respectively. The models were fitted with the same
intention as per the standard PSMs – that is, to provide
a parametric estimate of the survivor function over time.
The spline-based PSMs were fitted with 1, 2, or 3 in-
ternal knots, considered to provide a sufficiently broad
number of alternative models to choose between, avoid-
ing the use of more than 3 knots (equivalent to more
than 4 degrees of freedom) as the output may be un-
stable [29]. Knot locations were selected according to
the percentiles of the log-uncensored survival times (as
previous research has shown the determination of knot
locations does not appear critical for good fit) [31, 32].
Based on the selection of PSMs deemed appropriate
(following the assessment of the underlying hazard func-
tion), a comparison of PSMs was undertaken to deter-
mine those providing the ‘best fit’ to the trial data. The
determination of best-fitting models is (to an extent)
subjective, and so a range of methods were explored
covering statistical goodness-of-fit and prediction accur-
acy independent of model complexity.
Statistical goodness of fit
Four statistical goodness-of-fit scores were considered,
described in turn within Table 2, as well as the un-
adjusted maximized log-likelihood. The maximized log-
likelihood was considered as a simplistic representation
of the model providing the best fit to the data, without
any penalty considered with regards to the complexity of
the model fitted. For comparison to other measures of
statistical fit, the maximized log-likelihood was multi-
plied by − 2 (henceforth termed −2LL). It is noted that
within TSD14 that the use of the −2LL statistic should
only be considered when comparing nested models [9].
The presentation of the −2LL statistic is therefore pro-
vided primarily for context, such that the relative penal-
ties for complexity of other statistical goodness-of-fit
scores may be inferred.
Akaike and Bayesian information criteria (AIC and
BIC, respectively) were calculated, which are well docu-
mented in published literature, and described in detail
within TSD14 [9]. Due to the relatively-small sample size
of JM200, a corrected version of the AIC (AICc) was also
considered – literature suggested the AICc may be rele-
vant to consider when the ratio of the sample size and
number of model parameters is < 40 (in our example,
this would apply for PSMs with 3 or more parameters).
Finally, the Hannan–Quinn information criterion (HQC)
was calculated; which has been cited in a number of
studies to date, yet received little attention within the
context of PSMs [33, 34]. Within the context of this
study (where n = 88), the HQC considers a penalty for
model complexity between the AIC and BIC – the per-
parameter penalty is approximately 3.0 for the HQC,
versus 2.0 and 4.5 for the AIC and BIC, respectively.
Prediction accuracy
Previous studies which have attempted to assess the pre-
diction accuracy of PSMs within the context of cancer
immunotherapy have considered a range of techniques.
Ouwens et al. considered a combination of statistical
goodness-of-fit and area-under-the-curve estimates [28].
Bullement et al. presented a range of point estimates at
specific time points relative to the maturity of data from
each study [35].
For completeness, two summary statistics were consid-
ered: [1] the Kaplan-Meier (KM) versus modelled point-
estimate of survival, and [2] the restricted-mean survival
time (RMST) derived via area-under-the-curve (for the
KM versus predicted survival). Point-estimates provide a
simple representation of modelled survival accuracy at
specific timepoints. The RMST has previously been pro-
posed as an alternative to the conventional hazard ratio
used in the design of randomized controlled trials with a
time-to-event outcome, and is broadly aligned with the
expected outcome of economic modelling (i.e. if survival
curves are used to inform a cost-effectiveness analysis,
the estimation of life-years is based on an area-under-
the-curve calculation) [36].
Summary statistics were considered at key timepoints
relating to the maturity of each data cut. The minimum
and maximum follow-up time for each patient was con-
sidered for each data cut, as well as the mid-point between
these times. The resultant timepoints corresponded to
1Natural (or ‘restricted’) splines limit the estimation of the model
within the boundary knots (as extending beyond these boundaries is
generally understood to lead to a poorer fit). Cubic splines consider a
polynomial of order 3 – the smallest order which allows an inflexion
in the transformation of the survivor function.
Table 2 Measures of statistical goodness-of-fit
Acronym Full name Formula
−2LL −2 ×maximised log − likelihood −2LL = 2 log(L)
AIC Akaike information criterion AIC = 2k − 2 log(L)
AICc Akaike information
criterion (corrected)
AICc ¼ 2k−2 logðLÞ þ 2k
2þ2k
n−k−1
HQC Hannan – Quinn information
criterion
HQC = 2klog(log(n)) − 2
log (L)
BIC Bayesian information criterion BIC = log(n)k − 2 log(L)
Key: k Number of model parameters; L Maximized likelihood function; log
Natural logarithm; n Number of data points (sample size)
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(approximately) 6-monthly intervals from 12 to 48
months. Estimated survival at 36months is of particular
importance as this is the latest point in time for which the
KM estimate of survival may be considered fixed due to
all living patients having been followed up for at least 36
months.
In addition to these objective measures of prediction
accuracy, a visual assessment of PSM fit was also consid-
ered. For simplicity, the most notable estimates are pro-
vided within this article, and an exhaustive presentation
of each model is provided as supplementary material.
Results
Assessment of data
The available data from each of the four data cuts of the
JM200 trial are presented as KM curves Fig. 1. Over
time a plateau in the OS curve has emerged, indicating
that the specification of a PSM incapable of reflecting
time-varying hazards is unlikely to yield a good fit to the
available data, and consequently would not be expected
to provide a plausible extrapolation. Of particular note is
the number of patients at risk for each data cut at spe-
cific points in time – while estimates of 2.5-year (30-
month) OS for the two latest data cuts were within 2%
of each other (34.5 and 33.4%, for the 24- and 36-month
data cuts, respectively); the number of patients at risk at
this time in the later data cut is noticeably larger (n = 8
versus n = 28).
The smoothed hazard plots produced for each data
cut are provided in Fig. 2. As expected, the plots for each
data cut exhibit a non-constant hazard rate over time.
Further to this, the hazard function appears to be non-
monotonic (i.e. the hazard appears to increase and then
decrease). Based on this assessment, the lognormal, log-
logistic and generalized gamma PSMs would be expected
to provide a reasonable fit to the data, as would the
spline-based PSMs. However, the exponential, Weibull,
and Gompertz PSMs are unlikely to provide a plausible
OS extrapolation, due to the relative inflexibility of these
models; and were therefore not considered further.
Statistical goodness of fit
The statistical goodness-of-fit scores for each of the
PSMs are presented in Table 3. Unsurprisingly, the non-
penalized −2LL score demonstrated a clear preference
for the more flexible 3-knot spline-based PSMs across
all four data cuts, given that these models have the most
parameters and thus may be considered to have the
greatest freedom to best fit to data. The standard lognor-
mal PSM was shown to have the lowest goodness-of-fit
scores of all PSMs fitted to the 12- and 18-month data
cuts. Other PSMs shown to provide a good fit were the
log-logistic, 1-knot hazard, and 1-knot odds models.
Each of the four goodness-of-fit criteria (AIC, BIC,
AICc, and HQC, which trade-off model fit and complex-
ity) were generally in agreement, though the AIC (which
Fig. 1 Overall survival data from Part A of the JAVELIN Merkel 200 clinical trial. Key: mFU, minimum follow-up; mo, month(s)
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has the lowest penalty for model complexity) was shown
to exhibit an ‘earlier’ preference (with regards to com-
paring scores across the four data cuts) for a spline-
based PSM (the second-best AIC from the 12- and 18-
month data cuts was for the 1-knot odds PSM). In the
latest (36-month) data cut, the preferred PSM measured
by all four criteria was the 1-knot hazard spline. Notably,
even some of the 2- and 3-knot spline-based PSMs
yielded a better statistical goodness-of-fit than the log-
normal PSM fitted to the 36-month data cut (which was
considered the best-fitting PSM in the earlier data cuts).
Prediction accuracy
To compare the prediction accuracy of models of differ-
ing complexity over each data cut, the lognormal, log-
logistic, 1-knot odds, and 1-knot normal PSMs were se-
lected for consideration. These models were selected
owing to their statistical goodness-of-fit scores, as well
as the fact that the odds and normal spline-based PSM
are extensions to the log-logistic and log-normal stand-
ard PSMs, respectively. These models are provided for
each data cut in Fig. 3 for a timeframe of 5 years.
Visual inspection of the PSMs fitted to each data cut
demonstrates increasingly greater estimates of longer-
term OS, which is unsurprising as the maturing data
from JM200 show an increasingly clearer plateau in the
KM curve. In addition, a comparison of the best fitting
standard and spline-based PSMs for each data cut show
spline-based PSMs consistently provide estimates closer
to the ‘true’ OS, although both under-estimate OS as
demonstrated in the 36-month data cut.
An excerpt of the prediction accuracy results based on
the summary statistics are provided in Table 4 (complete
results are provided in the supplementary appendix).
When comparing PSM fits from the three earlier data
cuts to the KM curve for the latest data-cut, it may be
inferred that none of the models (standard or spline-
based) provided an estimate of 3-year survival greater
than or equal to the ‘true’ value of approximately 32.1%.
The closest fit was achieved using the 24-month data
cut by the 3-knot hazard spline (31.7%). The model fit-
ted to the 12-month data cut which yielded the closest
estimates to 36-month survival was the 1-knot odds
spline-based PSM (25.5%). These findings conflict with
the output of the statistical goodness-of-fit statistics,
which suggest the spline-based PSMs may over-fit to the
data.
Based on the earlier two data cuts, the modelled and
KM-estimated RMST values are broadly comparable
taken at the maximum follow-up time for each data cut
(of the ‘best fitting’ models, the largest under-estimate
was 0.3 months). However, when comparing the same
models with the latest (36-month) KM curve, the spline-
based models provided a closer fit (spline-based models
Fig. 2 Smoothed hazard plots from Part A of the JAVELIN Merkel 200 clinical trial. Note: Owing to the sample size of JAVELIN Merkel 200 Part A
(n = 88 patients), the max.time argument required by the muhaz function was set to the minimum follow-up time for each data cut.
Consequently, the smoothed hazard estimate for each data cut is presented within this figure for a limited time period
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Table 3 Statistical goodness-of-fit scores of fitted models
Statistic Model 12mo mFU 18mo mFU 24mo mFU 36mo mFU
-2LogL Log-logistic 375.3 429.4 453.5 483.0
Log-normal 373.7 427.5 451.3 480.5
Gen Gamma 373.3 426.5 448.7 475.0
1-knot Hazard 373.3 426.5 448.0 471.9
1-knot Odds 373.3 426.3 447.8 472.5
1-knot Normal 373.4 426.6 448.8 474.2
2-knot Hazard 373.4 426.5 447.4 470.8
2-knot Odds 373.3 426.3 447.3 471.3
2-knot Normal 373.2 426.2 (2) 447.2 471.1
3-knot Hazard 372.7 (3) 426.4 446.6 (2) 469.6 (1)
3-knot Odds 372.5 (2) 426.3 (3) 446.7 (3) 469.9 (3)
3-knot Normal 372.2 (1) 426.1 (1) 446.6 (1) 469.8 (2)
AIC Log-logistic 379.3 433.4 457.5 487.0
Log-normal 377.7 (1) 431.5 (1) 455.3 484.5
Gen Gamma 379.3 432.5 454.7 (3) 481.0
1-knot Hazard 379.3 (3) 432.5 (3) 454.0 (2) 477.9 (1)
1-knot Odds 379.3 (2) 432.3 (2) 453.8 (1) 478.5 (2)
1-knot Normal 379.4 432.6 454.8 480.2
2-knot Hazard 381.4 434.5 455.4 478.8 (3)
2-knot Odds 381.3 434.3 455.3 479.3
2-knot Normal 381.2 434.2 455.2 479.1
3-knot Hazard 382.7 436.4 456.6 479.6
3-knot Odds 382.5 436.3 456.7 479.9
3-knot Normal 382.2 436.1 456.6 479.8
AICc Log-logistic 379.4 (2) 433.5 457.6 487.2
Log-normal 377.8 (1) 431.7 (1) 455.5 484.7
Gen Gamma 379.6 432.8 455.0 (3) 481.3
1-knot Hazard 379.6 432.8 (3) 454.3 (2) 478.2 (1)
1-knot Odds 379.5 (3) 432.6 (2) 454.1 (1) 478.8 (2)
1-knot Normal 379.6 432.9 455.0 480.5
2-knot Hazard 381.9 434.9 455.9 479.3 (3)
2-knot Odds 381.8 434.8 455.8 479.7
2-knot Normal 381.7 434.7 455.7 479.6
3-knot Hazard 383.4 437.2 457.3 480.3
3-knot Odds 383.2 437.0 457.4 480.6
3-knot Normal 382.9 436.8 457.3 480.6
HQC Log-logistic 381.3 (2) 435.4 (3) 459.5 489.0
Log-normal 379.7 (1) 433.5 (1) 457.3 (3) 486.5
Gen Gamma 382.3 435.5 457.7 484.0
1-knot Hazard 382.3 435.5 457.0 (2) 480.9 (1)
1-knot Odds 382.3 (3) 435.3 (2) 456.8 (1) 481.5 (2)
1-knot Normal 382.4 435.6 457.8 483.2
2-knot Hazard 385.4 438.5 459.4 482.8 (3)
2-knot Odds 385.3 438.3 459.3 483.2
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Table 3 Statistical goodness-of-fit scores of fitted models (Continued)
Statistic Model 12mo mFU 18mo mFU 24mo mFU 36mo mFU
2-knot Normal 385.2 438.2 459.2 483.1
3-knot Hazard 387.7 441.4 461.6 484.6
3-knot Odds 387.4 441.3 461.7 484.9
3-knot Normal 387.2 441.1 461.6 484.8
BIC Log-logistic 384.2 (2) 438.4 (2) 462.4 492.0
Log-normal 382.7 (1) 436.5 (1) 460.3 (1) 489.5
Gen Gamma 386.8 440.0 462.1 488.4
1-knot Hazard 386.7 440.0 461.4 (3) 485.3 (1)
1-knot Odds 386.7 (3) 439.7 (3) 461.2 (2) 485.9 (2)
1-knot Normal 386.8 440.0 462.2 487.7 (3)
2-knot Hazard 391.3 444.4 465.3 488.7
2-knot Odds 391.2 444.2 465.2 489.2
2-knot Normal 391.1 444.1 465.1 489.0
3-knot Hazard 395.1 448.8 469.0 492.0
3-knot Odds 394.8 448.7 469.1 492.3
3-knot Normal 394.6 448.5 469.0 492.2
Key: AIC Akaike information criterion; AICc Akaike information criterion (corrected); BIC Bayesian information criterion; Hannan–Quinn information criterion; L
Maximized likelihood function; log Natural logarithm; mFU Minimum follow up; mo Month(s)
Note: For each of the scores presented above, a lower value indicates a better statistical goodness-of-fit. The “best” fitting model (i.e. the model with the lowest
score) is denoted with “(1)” after the score, and is shaded in dark grey. Models with ranks 2 and 3 are formatted similarly
Fig. 3 Fitted models from Part A of the JAVELIN Merkel 200 clinical trial. Notes: A, 12-month data cut; B, 18-month data cut; C, 24-month data
cut; D, 36-month data cut. Key: k, knot(s); KM, Kaplan-Meier; n, normal; o, odds.
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under-estimated 36-month RMST [17.5 months] by 0.4–
0.5 months, versus 0.5–1.2 months for the standard para-
metric models). For the 24-month data cut, the standard
parametric models over-estimated RMST by 0.2–0.4
months, whereas for the 36-month data cut, the stand-
ard parametric models over-estimated RMST by as
much as 0.9 months.
Based upon the original 12-month data cut, each of
the PSMs predicted 12-month survival within 1% of the
‘true’ value. Estimated 24-month survival ranged from
30.2% (log-logistic) to 34.0% (1-knot odds spline),
whereas the ‘true’ value (revealed in later data cuts) was
35.8% (with a preliminary estimate from the 12-month
data cut of 38.4%). The log-logistic and 1-knot odds
spline models based on the 12-month data cut both pro-
vided similar statistical goodness-of-fit scores (AIC and
BIC scores within 2 points of each other). Therefore,
based on the clinical expectation of a survival plateau,
similar statistical goodness-of-fit scores, and the
prediction accuracy results based on the summary statis-
tics presented, it may be reasonable to select the 1-knot
odds spline model. In later data cuts, this model was
shown to provide an under-estimate of survival, yet min-
imized the under-estimation of survival versus all other
options fitted based on the 12-month data cut (including
the log-logistic).
Discussion
This study presents an application and subsequent
validation of parametric survival modelling of multiple
pre-planned data cuts, using data from a case study
of avelumab for mMCC. Four data cuts were utilized
to demonstrate how initial projections were affected
when refitted with more complete data. While stand-
ard PSMs had the best statistical goodness-of-fit score
in earlier data cuts (determined from all four formal
goodness-of-fit criteria presented in our study); for
later data cuts, more flexible spline-based PSMs
Table 4 Prediction accuracy key findings
Data
cut




Fitted (earlier) data cut Latest (36-mo) data cut Fitted (earlier) data cut Latest (36-mo) data cut
12-mo KM estimates 51.8 32.1 8.7 17.5
12-mo Log-normal Best AIC, BIC −0.3 −10.2 −0.2 −0.9
12-mo Log-logistic Lowest RMST, PE −0.7 −11.5 −0.2 −1.2
12-mo 1-knot Odds Highest RMST, PE −0.8 −6.6 −0.3 −0.5
18-mo KM estimates 39.9 32.1 11.3 17.5
18-mo Log-normal Best AIC, BIC + 1.1 −8.7 + 0.0 −0.5
18-mo Log-logistic Lowest RMST, PE + 0.0 −9.8 − 0.0 − 0.8
18-mo 1-knot Odds Highest RMST + 1.2 −5.1 − 0.2 − 0.4
18-mo 3-knot Odds Highest PE + 1.1 −4.8 −0.2 − 0.4
24-mo KM estimates 35.8 32.1 13.5 17.5
24-mo 1-knot Odds Best AIC + 1.2 −2.0 + 0.0 + 0.0
24-mo Log-normal Best BIC −0.1 −6.0 + 0.4 + 0.1
24-mo Log-logistic Lowest RMST, PE −1.6 −7.4 + 0.2 −0.3
24-mo Gen Gamma Highest RMST + 1.2 −2.7 + 0.2 + 0.1
24-mo 3-knot Hazard Highest PE + 0.9 −0.4 −0.1 − 0.1
36-mo KM estimates 32.1 32.1 17.5 17.5
36-mo 1-knot Hazard Best AIC, BIC, highest PE + 1.4 + 1.4 + 0.2 + 0.2
36-mo 3-knot Hazard Lowest RMST + 0.9 + 0.9 −0.1 −0.1
36-mo Log-normal Highest RMST −2.3 − 2.3 + 0.9 + 0.9
36-mo Log-logistic Lowest PE −4.1 −4.1 + 0.4 + 0.4
Key: AIC Akaike’s information criterion; BIC Bayesian information criterion; Gen Generalized; mo Month(s); PE Point estimate; RMST Restricted mean survival time
Note: Negative values indicate that the model underestimates survival, whereas positive values indicate that the model overestimates survival. ‘Fitted’ refers to
the data cut from which the models were fitted (i.e. the data cut stated within the left-hand column), and so a comparison is made between a model fitted to a
given data cut and the Kaplan-Meier curve for this same data cut. ‘Latest’ refers to the 36-month data cut, and so a comparison is made between a model fitted
to the specified data cut (which may be earlier) and the Kaplan-Meier curve for the 36-month data cut. Models were included in this table if one or more of the
following criteria were met: (1) the model provided the ‘best’ AIC or BIC score, (2) the model provided either the ‘highest’ or ‘lowest’ estimate of RMST at 36
months, or (3) the model provided either the ‘highest’ or ‘lowest’ PE of survival at 36months. Where RMST estimates were tied (to the nearest 0.1 month), the
model with the lowest AIC or BIC was included here. Full prediction accuracy results are provided within the supplementary material
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provided the ‘best’ scores, as well as a more accurate
estimation of the pattern of survival over time. A
broader view of statistical goodness-of-fit scores
therefore appears critical in determining the best-
fitting model.
To date, a number of studies have attempted to estab-
lish the prediction accuracy of extrapolation methods
used for immune-checkpoint inhibitors. Gibson et al.,
(2017) validated the extrapolation of spline-based PSMs
to predict progression-free survival for advanced melan-
oma patients treated with ipilimumab, nivolumab, or the
combination of the two treatments enrolled within the
CheckMate 067 trial using external data from patients
treated with ipilimumab monotherapy [37]. Bullement
et al., (2019) also performed a validation of survival
extrapolation techniques in advanced melanoma, using
re-created data from two data cuts of the pivotal ipilimu-
mab CA184–024 trial [38]. Ouwens et al., (2019) ex-
plored a broad range of extrapolation methods using
data for patients with non-small-cell lung cancer from
the ATLANTIC trial of durvalumab [28].
Within the context of our case study, Lanitis et al.,
(2019) presented a range of alternative extrapolation ap-
proaches, including landmark analyses based on re-
sponse and progression status [39]. Due to data
availability at the time of analysis, each of these studies
were conducted using only two data cuts (i.e. one data
cut for estimation, and a second for validation). As the
majority of studies have been conducted in melanoma, it
is unclear whether or not the findings are generalizable
to other cancer types, particularly as the possibility of
long-term survival for melanoma patients was estab-
lished prior to the introduction of immune-checkpoint
inhibitors – historical estimates of 10-year survival for
Stage IV melanoma patients ranged from 7 to 20%
(dependent on metastatic site) [40, 41].
This study makes use of four formal, pre-planned data
cuts from the same registrational trial. The availability of
several data cuts from the same study allows for a more
in-depth assessment of appropriate PSM fits versus pre-
vious studies wherein only one additional data cut is
usually available, without the need to generalize across
different studies (e.g. by comparing to registry and/or
historical control data). By comparing the PSMs and
corresponding statistical goodness-of-fit scores across
each data cut, an emergent picture may be ascertained
regarding which PSM could be reasonably selected.
When fitting the PSMs, published guidance NICE
DSU TSD14 was followed, and a systematic approach to
appropriate model selection was adopted. In addition to
standard models, spline-based PSMs were also fitted to
provide a broad range of survival estimates. While to
date these models have not been used extensively, previ-
ous studies have highlighted the potential role of flexible
PSMs (including spline-based PSMs) within the context
of complex hazard functions (which may be due to a
combination of the disease area, mechanistic properties
of the intervention, or clinical trial study design) [28, 32,
38, 39]. In addition to exploring a range of extrapolation
methods, this study illustrates the value of assessing the
available trial data via hazard plots in order to inform
appropriate model selection. The use of hazard plots
and/or other diagnostic plots is advocated in available
guidance (including TSD14), though these plots are
rarely used to their full potential [9].
Used in combination with hazard-based plots, the po-
tential importance of understanding and interpreting
statistical goodness-of-fit scores was highlighted by our
study. Where goodness-of-fit scores disagree and/or dif-
ferent PSMs exhibit scores within close proximity to one
another, it may be useful to explore further why this is
the case (and thus infer if there is a clear reason to favor
one model or score over the other). Burnham and An-
derson (2002) highlight a ‘rule of thumb’ concerning the
AIC, which states that if the difference between the best
and an alternative PSM is ≤2 points, there is “substantial
empirical support” for the alternative, poorer-fitting
PSM (and so this model should not necessarily be
rejected based on the AIC alone) [34]. Hilbe (2011) of-
fers a slightly different rule of thumb, noting that if the
difference is ≤2.5 points there is “no difference” in the
models; and if the difference is ≤6.0 points, the alterna-
tive PSM should only be rejected if the sample size n >
256 [42].
In our motivating example, the sample size was n =
88, and the lognormal PSM was preferred for the two
earlier data cuts. However, there was emergent evi-
dence of the next best-fitting model (1-knot odds
spline-based PSM) providing a reasonable fit, and a
potentially more accurate estimate of survival. The
difference in AIC for the models was approximately
1.6, illustrating the importance of looking beyond the
best-fitting model, should evidence be available to
suggest doing so (in our example, this may be based
on the more accurate estimate of the RMST up until
24 months). While potentially challenging to interpret
while data are maturing, we believe the interpretation
of statistical goodness-of-fit scores is currently an under-
used tool that may help aid selection of appropriate models
outside of simply choosing the model with the lowest score.
However, statistical goodness-of-fit scores only reflect the
goodness-of-fit within the observed period, and so should
not be considered as a comprehensive representation of
overall model fit.
Further to the notion of statistical goodness-of-fit scores
potentially being an underused tool in model selection,
the choice of statistical fit score to inform model selection
is seldom discussed. Literature notes that both the BIC
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and HQC are not true estimators of Kullback–Leibler
(KL) divergence (which is essentially a measure of how
one probability distribution [in our case, the distribution
of survival times estimated via a PSM] is different from
another), and are instead focused upon the selection of
the ‘true’ model which exists and is within the set of fitted
PSMs being considered [34]. Conversely, the AIC and
AICc are focused upon the identification of the model that
minimizes the KL divergence of the model and the ‘true’
underlying function being estimated (for which the ‘true’
model does not necessarily exist) [34].
While a relatively subtle difference in model inter-
pretation, given the context of our motivating ex-
ample (that is, increasingly maturing data cuts which
are expected to gradually reveal a more accurate esti-
mate of the underlying survivor function), it would
seem more appropriate to consider goodness-of-fit
scores that do not require the assumption of a ‘true’
model existing and being present within a set of
models to choose between. More specifically, simple
parametric models fitted to preliminary data cuts
might not consider specific characteristics of the ‘true’
survival pattern that is impacted by the maturity of
data, delayed treatment effects, the potential for long-
term survivors, and other relevant real-world aspects.
We recommend the choice of goodness-of-fit score to
inform model selection should therefore be deter-
mined within the context of the underlying decision
problem to ascertain which score(s) may be most ap-
propriate under specific circumstances. Alternatively,
consideration of a broad range of scores may aid
model selection (including the lesser-used HQC,
which like the AIC exhibited a preference for the 1-
knot odds spline based on the 24-month data cut, yet
the BIC did not), given that it is often the case that
only AIC and BIC are considered in submission to
NICE (based on TSD14 guidance) [9].
The importance of appropriate survival extrapolation
is particularly highlighted within the context of HTA, as
noted within NICE TSD 14: “different methods have
varying functional forms and are likely to result in differ-
ent survival estimates, with the differences potentially
large – particularly when a substantial amount of ex-
trapolation is required” [9]. A model under-estimating
RMST by approximately 1 month would translate to an
under-estimate in life-years gained of 0.08, equivalent to
approximately 0.06 (undiscounted) QALYs (assuming a
utility value of 0.71 per the published cost-utility analysis
of avelumab in mMCC) [43]. Though a seemingly small
decrease in QALYs gained, were this decrement applied
to the published base-case cost-utility results, the incre-
mental cost-effectiveness ratio (ICER) would increase by
approximately £1000. The ICER would increase further
were the extrapolated portion of the curve also
considered to under-estimate survival markedly (as may
be expected given the under-estimate of the RMST).
NICE TSD 14 comments further on the difficulty in
justifying the plausibility of the extrapolated portion of
the survival model chosen, noting that this is likely to
greatly influential on the estimated mean survival. It is
recommended that model choice is based on the use of
external data sources, biological plausibility, or clinical
expert opinion. In the context of our motivating ex-
ample, no external data sources were available to inform
model selection, and so clinical expert opinion and bio-
logical plausibility have increased importance when
selecting between alternative models.
Furthermore, we focused solely on the use of bio-
logical plausibility and clinical expert opinion as a means
of selecting from a suite of models that had already been
fitted (as opposed to factoring this information within
the model fitting itself) – models that make use of exter-
nal information within the model fitting process may
also be important to consider, though were beyond the
scope of our research question. An example of such ap-
proaches includes the relative survival framework, for
which Dickman and Coviello (2015) present several
worked examples within the context of population-based
cancer registries [44]. Using this approach cause-specific
survival is estimated relative to a comparable group from
the general population. While this approach may yield
improved estimates of survival, the data requirements
are increased (through the need to specify a comparable
group) and longer-term cause-specific hazards may still
be difficult to estimate.
There are a number of alternative extrapolation
methods that were not considered within our study.
Lanitis et al. considered alternative models based on
separating the population and/or survival outcomes
based on intermediate outcome assessment (i.e. pro-
gression or response) [39]. Othus et al., (2017)
demonstrated the potential role of mixture-cure mod-
elling, wherein a proportion of patients are expected
to be ‘statistically-cured’, and are subject to a hazard
of death per the age- and sex-adjusted general popu-
lation [45]. In addition to mixture-cure models,
Ouwens et al., (2019) note the potential role of other
mixture models (which do not assume a ‘cured’ frac-
tion) and Lanitis et al. presented landmark analyses
that may improve prediction accuracy) [28, 39]. While
these techniques may yield reasonable extrapolations,
the focus of our study was on the use of purely para-
metric approaches such that any differences in fit
and/or long-term estimation may be considered as a
factor of the model selected (and not any other deci-
sions, such as the existence of distinct patient groups,
or clinically-relevant timepoints). Furthermore, statis-
tical goodness-of-fit scores should not be compared
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for models which utilize different sources of external
information (such as background mortality rates),
hence the omission of these models within our study
allows for a valid comparison of statistical goodness-
of-fit scores.
Data from the JM200 trial allow for a comparison of
PSM projection accuracy up to at least 36 months (per
the minimum follow-up time for patients in the latest
data cut), beyond which extrapolations remain. Obtain-
ing repeated data cuts from clinical trials is subject to
practical limitations, and so while further data collection
is necessary to truly determine the most plausible ex-
trapolation technique within this case study, we may
never truly be able to validate the entire projection of
OS. Plans for the publication of repeated data cuts
should be specified within the design of clinical trials
with survival-based endpoints where possible, in order
to further understand how patterns of survival may
change over time.
Conclusions
The findings of the study show that while more flexible
models (such as spline-based PSMs) may offer sub-
optimal statistical goodness-of-fit scores in early data
cuts (due to the penalties applied for model complexity),
they may be able to more accurately reflect emergent
complex hazard functions, provide estimate more closely
aligned with biological plausibility/ clinical expert opin-
ion, and consequently yield more credible longer-term
survival estimates. As such, a thorough exploration of
PSMs outside of the standard six PSMs is encouraged
where complex hazard functions are expected, as well as
a detailed exploration of statistical goodness-of-fit scores
and their interpretation.
While data from the JM200 trial are specific to mMCC
patients treated with avelumab, the implications of the
analysis performed using our motivating example may
be useful more broadly when choosing between alterna-
tive survival extrapolation methods – that is, further in-
spection of statistical goodness-of-fit scores specifically
may aid understanding of the likely pattern of survival as
interim data mature. We urge the preferred selection of
survival extrapolation to be based on a multitude of fac-
tors including statistical goodness-of-fit, visual fit, bio-
logical plausibility, hazard plots and other relevant
diagnostic plots, and encourage the use of multiple data
cuts (both earlier and later) and clinical expert opinion
to select and validate extrapolations where possible.
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